NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of a New Dermal Patch for Parkinson’s Disease
Ness Ziona, October 6, 2010 / — NeuroDerm, Ltd. was informed today that it was awarded a grant of $1M by The Michael J. Fox Foundation for Parkinson’s Research. These funds will support the next clinical study with ND0611, a new dermal patch for the treatment of Parkinson’s disease, as part of the Foundation’s prestigious Clinical Intervention Awards 2010 program. This study will evaluate the safety, tolerability, levodopa pharmacokinetics, and possible clinical benefits of ND0611 in advanced Parkinson’s disease patients.
ND0611 is a proprietary drug formula that enables, for the first time, the continuous administration of carbidopa via a sub-cutaneous dermal patch. Carbidopa is conventionally administered orally with levodopa to prevent its breakdown. Subcutaneous carbidopa delivery may permit more continuous levels of levodopa to be maintained in the brain thus helping to manage motor fluctuations in Parkinson’s disease patients.
In this next study, ND0611 will be administered to advanced Parkinson’s disease patients together with standard levodopa products (Sinemet®, Stalevo® and Sinemet® CR). The study is designed to learn if the subcutaneously-administered Carbidopa enhances the continuity of levodopa blood concentrations and improves the consistency of levodopa effect in the treatment of Parkinson’s disease by showing if the study’s subjects experience less “off” time as compared to conventional carbidopa-levodopa regimens.
“The enormous show of confidence by The Michael J. Fox Foundation for Parkinson’s Research in this new therapeutic approach for Parkinson’s disease strengthens our efforts to develop innovative treatments for the many unmet needs of patients with this disorder, ” said Oded S. Lieberman, PhD, NeuroDerm’s Chairman and CEO. “It also underscores NeuroDerm’s deep commitment and expertise in the development of novel therapeutics for diseases of the central nervous system”.
NeuroDerm is an emerging pharmaceutical company that develops novel therapeutic dermal patches for the treatment of CNS diseases. NeuroDerm’s technology is based on proprietary reformulations of well-established oral drugs, whose low bioavailability is the major impediment to better efficacy. The company’s lead product is ND0611, a revolutionary skin patch for the treatment of Parkinson’s disease. Additional products for the treatment of Parkinson’s disease, ADD, ADHD, schizophrenia and Alzheimer’s disease are in different stages of development. NeuroDerm is headquartered in the Weizmann Science Park, Ness Ziona, Israel.